3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
427
Neoplasms, Plasma Cell
68
Lymphoma, Mantle-Cell
66
Lymphoma
65
Recurrence
64
Lymphoma, Non-Hodgkin
43
Lymphoma, Follicular
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
36
Lymphoma, Large B-Cell, Diffuse
34
Waldenstrom Macroglobulinemia
33
Lymphoma, B-Cell, Marginal Zone
30
Leukemia, Lymphocytic, Chronic, B-Cell
28
Neoplasms
24
Carcinoma, Non-Small-Cell Lung
24
Immunoglobulin Light-chain Amyloidosis
23
Leukemia
21
Hodgkin Disease
17
Lymphoma, B-Cell
14
Burkitt Lymphoma
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Myelodysplastic Syndromes
13
Lymphoma, Large-Cell, Anaplastic
13
Hematologic Neoplasms
13
Immunoblastic Lymphadenopathy
12
Breast Neoplasms
12
Mycosis Fungoides
11
Lymphoma, T-Cell, Cutaneous
11
Lymphoma, Large-Cell, Immunoblastic
11
Congenital Abnormalities
11
Interventions
pembrolizumab
4
envafolimab
3
Nivolumab
3
Injections
2
trifluridine tipiracil drug combination
1
tebentafusp
1
surufatinib
1
sintilimab
1
linifanib
1
fludarabine
1
cobimetinib
1
TAK-981
1
Ipilimumab
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Combined Modality Therapy
1
Bortezomib
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Advanced or Metastatic Solid Tumors
×
Bortezomib
×
Clear all
NCT02220049
2016-03-25
VELDAY
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
Completed
18 enrolled